Abstract: A container when assembled includes a body, a cover, a lower grinding component, and an upper grinding component. The body includes a primary storage area compartment, the lower grinding component includes a grinding area compartment, and the upper grinding component includes a secondary storage area compartment. The upper grinding component partially nests within the lower grinding component. The lower grinding component defines a recess comprising the grinding area compartment. The upper grinding component is inserted into and partially received within the recess of the lower grinding component to form a grinder. The lower grinding component partially nests within the body of the container and the cover fits over the upper grinding component and partially over the lower grinding component when the cover is secured to the body of the grinder, whereby the grinder is completely enclosed within the body and cover of the container.

Abstract: A container when assembled includes a body, a cover, a lower grinding component, and an upper grinding component. The body includes a primary storage area compartment, the lower grinding component includes a grinding area compartment, and the upper grinding component includes a secondary storage area compartment. The upper grinding component partially nests within the lower grinding component. The lower grinding component defines a recess comprising the grinding area compartment. The upper grinding component is inserted into and partially received within the recess of the lower grinding component to form a grinder. The lower grinding component partially nests within the body of the container and the cover fits over the upper grinding component and partially over the lower grinding component when the cover is secured to the body of the grinder, whereby the grinder is completely enclosed within the body and cover of the container.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: A safety device with fall arrest and descending modes includes a housing, a drum, a lifeline, first and second brake assemblies, and a control. The drum is rotatably operatively connected to the housing. The lifeline has an intermediate portion interconnecting a first end and a second end. The first end is operatively connected to the drum. The first and second assemblies are operatively connected to the drum. The control is operatively connected to the first and second brake assemblies and has a first position and a second position. The first position selectively engages the first brake assembly in a descending mode and the second position selectively engages the second brake assembly in a fall arrest mode.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: A system and method are provided for generating time resolved series of angiographic volume data having flow information. The system and method are configured to receive angiographic volume data acquired from a subject having received a dose of a contrast agent using an imaging system and process the angiographic volume data to generate angiographic volume images. The angiographic volume data is processed to select a seed vessel in the vessel network, determine a plurality of branch vessels connected to the seed vessel and extending to form a vessel network, determine independent and dependent vessels in the vessel network, apply a flow model to the vessel network, and generate a flow map to be displayed with the angiographic volume images to illustrate time-resolved vascular volumes displaying flow within the vessel network.

Abstract: This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: A system and method are provided for generating time resolved series of angiographic volume data having flow information. The system and method are configured to receive angiographic volume data acquired from a subject having received a dose of a contrast agent using an imaging system and process the angiographic volume data to generate angiographic volume images. The angiographic volume data is processed to select a seed vessel in the vessel network, determine a plurality of branch vessels connected to the seed vessel and extending to form a vessel network, determine independent and dependent vessels in the vessel network, apply a flow model to the vessel network, and generate a flow map to be displayed with the angiographic volume images to illustrate time-resolved vascular volumes displaying flow within the vessel network.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.